MARKET

XERS

XERS

Xeris Biopharma Holdings
NASDAQ
8.32
-0.09
-1.07%
After Hours: 8.32 0 0.00% 19:34 07/24 EDT
OPEN
8.42
PREV CLOSE
8.41
HIGH
8.54
LOW
8.29
VOLUME
1.18M
TURNOVER
--
52 WEEK HIGH
10.08
52 WEEK LOW
4.870
MARKET CAP
1.44B
P/E (TTM)
149.91
1D
5D
1M
3M
1Y
5Y
1D
Press Release: Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026
Dow Jones · 2d ago
Xeris Biopharma to report Q2 results, host conference call
PUBT · 2d ago
Weekly Report: what happened at XERS last week (0713-0717)?
Weekly Report · 5d ago
Xeris Biopharma Eliminates 2028 Convertible Notes Via Exchanges
TipRanks · 07/17 21:26
Weekly Report: what happened at XERS last week (0706-0710)?
Weekly Report · 07/13 09:27
Analysts Are Bullish on These Healthcare Stocks: Alterity Therapeutics (ATHE), Vera Therapeutics (VERA)
TipRanks · 07/08 13:10
Xeris Biopharma CFO Steven Pieper disposes of 45,000 common shares worth $385,876.20
PUBT · 07/07 21:11
Weekly Report: what happened at XERS last week (0629-0703)?
Weekly Report · 07/06 09:28
More
About XERS
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company focused on improving patient lives by developing and commercializing products across a range of therapies. It has three commercially available products: Recorlev, Gvoke, and Keveyis. Recorlev is for the treatment of endogenous Cushing’s syndrome. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is a therapy for primary periodic paralysis. It also has a pipeline of development programs led by XP-8121, a phase III-ready, once-weekly subcutaneous injection for hypothyroidism. It is pursuing formulation and development partnerships to apply its XeriSol and XeriJect formulation technologies to enhance the drug delivery and clinical profile of other companies’ proprietary drugs and biologics. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative.

Webull offers Xeris Biopharma Holdings Inc stock information, including NASDAQ: XERS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XERS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XERS stock methods without spending real money on the virtual paper trading platform.